Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105489 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jiahao Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Over 120 small-molecule kinase inhibitors (SMKIs) have been approved worldwide for treating various diseases, with nearly 70 FDA approvals specifically for cancer treatment, focusing on targets like the epidermal growth factor receptor (EGFR) family. Kinase-targeted strategies encompass monoclonal antibodies and their derivatives, such as nanobodies and peptides, along with innovative approaches like the use of kinase degraders and protein kinase interaction inhibitors, which have recently demonstrated clinical progress and potential in overcoming resistance. Nevertheless, kinase-targeted strategies encounter significant hurdles, including drug resistance, which greatly impacts the clinical benefits for cancer patients, as well as concerning toxicity when combined with immunotherapy, which restricts the full utilization of current treatment modalities. Despite these challenges, the development of kinase inhibitors remains highly promising. The extensively studied tyrosine kinase family has 70% of its targets in various stages of development, while 30% of the kinase family remains inadequately explored. Computational technologies play a vital role in accelerating the development of novel kinase inhibitors and repurposing existing drugs. Recent FDA-approved SMKIs underscore the importance of blood–brain barrier permeability for long-term patient benefits. This review provides a comprehensive summary of recent FDA-approved SMKIs based on their mechanisms of action and targets. We summarize the latest developments in potential new targets and explore emerging kinase inhibition strategies from a clinical perspective. Lastly, we outline current obstacles and future prospects in kinase inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
Zitieren
APA
Li, J., Gong, C., Zhou, H., Liu, J., Xia, X., Ha, W., Jiang, Y., Liu, Q., & Xiong, H. (2024). Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105489
Vancouver
Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, et al. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105489
BibTeX
@article{Li2024,
author = {Li, Jiahao and Gong, Chen and Zhou, Haiting and Liu, Junxia and Xia, Xiaohui and Ha, Wentao and Jiang, Yizhi and Liu, Qingxu and Xiong, Huihua},
title = {Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105489}
}
EUVIMED